New Nasal Spray Vaccine Aims to Transform TB Treatment

Researchers from Johns Hopkins Medicine have created a new DNA vaccine that is administered through a nasal spray, aimed at revolutionizing tuberculosis (TB) treatment. This vaccine targets dormant bacteria that are difficult to eliminate with conventional antibiotics, which often lead to relapses.

The study, led by Styliani Karanika, an assistant professor of medicine at Johns Hopkins University School of Medicine, demonstrated that the vaccine significantly reduced lung inflammation and helped clear TB bacteria in animal studies. The vaccine is designed to enhance the effectiveness of existing drug treatments, particularly for hard-to-treat cases of TB, including multidrug-resistant forms.

Unlike traditional vaccines, this nasal spray allows for direct activation of the immune response in the lungs, providing a strong and lasting T-cell response that could protect patients for at least six months. While the vaccine has shown promise in animal studies, further testing is required before it can enter human clinical trials.

This advancement is seen as a crucial step in addressing the global health challenge posed by TB, which infects 10 million people and kills 1.2 million annually.